Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Gynecol Endocrinol ; 16(2): 143-50, 2002 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-12012625

RESUMO

Gonadotropin releasing hormone agonists (GnRHa) are commonly used during in vitro fertilization and embryo transfer (IVF/ET) treatment cycles to downregulate the hypothalamic-pituitary-ovarian axis prior to ovarian stimulation with gonadotropins. It has been suggested that profound downregulation may have an adverse effect on IVF/ET outcome. The aim of this study was to examine the relationship between the degree of downregulation and IVF/ET outcome. A retrospective analysis was performed on 151 IVF/ET cycles conducted over a six month period. Intensity of downregulation was assessed using measurements of serum concentrations of luteinizing hormone (LH) and estradiol (E2) made at the end of a two week downregulation period. There was no correlation between serum concentration of LH (whether used alone or in combination with E2) and IVF/ET pregnancy rates. However, those subjects who were more suppressed according to the E2 concentration (< 148 pmol/l, [median]) required significantly more gonadotropins (3306 IU versus 2863 IU, p < 0.05) and took longer for follicles to reach maturity (10.9 days versus 9.7 days, p < 0.05). They also had a lower pregnancy rate per embryo transfer (10.4% versus 28.6%, p < 0.05) compared with those having a higher basal E2 concentration. We conclude from this study that the basal serum E2 concentration rather than the LH concentration is a more sensitive indicator of the intensity of downregulation by GnRHa and it may be a better predictor of IVF outcome.


Assuntos
Transferência Embrionária , Fármacos para a Fertilidade Feminina/administração & dosagem , Fertilização in vitro , Hipotálamo/efeitos dos fármacos , Ovário/efeitos dos fármacos , Hipófise/efeitos dos fármacos , Adulto , Busserrelina/administração & dosagem , Busserrelina/efeitos adversos , Estradiol/sangue , Feminino , Fármacos para a Fertilidade Feminina/efeitos adversos , Humanos , Hipotálamo/fisiologia , Hormônio Luteinizante/sangue , Ovário/fisiologia , Hipófise/fisiologia , Gravidez , Estudos Retrospectivos , Sensibilidade e Especificidade , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA